Schedule 13G ownership disclosure

Xenon Pharmaceuticals Inc

COMMON STOCK · CUSIP: 98420N105

Event date: 2026-10-31

Filing-level shares
9,996,124
Percent of class
10.3%
  • T. Rowe Price Investment Management, Inc.

    Shares: 9,996,124 · Class: 10.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001897612-26-000704
Form type
SCHEDULE 13G/A
Filer
T. Rowe Price Investment Management, Inc.
CIK
CIK 1897612
Filed
Nov 06, 2026
Reporting period
Oct 31, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub